Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

Findings Also Showed Patients Experienced Improvements in Quality of Life Measures and Fatigue Despite Treatment with Other Anti-TNFs or Methotrexate

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue. The data from the randomized, double-blind, placebo- controlled studies in patients with active moderate to severe rheumatoid arthritis (RA) were presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. The first trial was in patients who were previously treated with anti-tumor necrosis factor (TNF) agents and the second study was in patients who were active despite ongoing treatment with methotrexate.

"In addition to reducing signs and symptoms, these data show improvement in important measures of functional ability and quality of life," said Jonathan Kay, M.D., Director, Clinical Trials, Rheumatology Unit, Massachusetts General Hospital; Associate Clinical Professor of Medicine, Harvard Medical School, and lead study investigator. "These data support the potential benefit of golimumab in patients previously treated with anti-TNF therapies or methotrexate."

In the study, GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER), 50 mg and 100 mg doses of golimumab were studied in patients who had active RA and who were previously treated with anti-TNF treatments, but where anti-TNF treatment had been discontinued due to lack of efficacy (58 percent), intolerance (17 percent) or other reasons (40 percent). Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if they were receiving them at baseline. Golimumab-treated patients who had discontinued previous anti-TNF treatment for any reason experienc
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Pressure BioSciences, Inc. (OTCQB: PBIO) ... will host a teleconference to discuss its First Quarter ... The teleconference information is provided below: Date: ... Time (EDT) Dial-in: (800) 875-3456 (U.S.); (800) ... Passcode: VS22823 For those unable to participate ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
(Date:5/23/2013)... May 23, 2013 Bed bugs already cost ... pests is still ongoing, a report from kmov.com suggested that ... the bed bug treatment. Meanwhile, to be of help, My ... the costly bed bug exterminator service. , The ... AHA has so far spent $35,000 for bed ...
(Date:5/23/2013)... 23, 2013 Ralph Huber, President of ... emergency management products and emergency survival kits would be ... was made at the quarterly executive board meeting on May ... of silence for the Oklahoma tornado victims and used the ... of their emergency kits is paramount. “When disaster strikes,” ...
Breaking Biology Technology:Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits 2
... Inc. (IVT),a vaccine development company, unveiled today its ... to increase the efficacy and,strength of vaccines. IVT ... "The results from our preclinical studies demonstrate ... remarked Marc Mansour, vice,president of research and development ...
... Biophysicist Brings Expertise in Single Molecule Fluorescence and ... Nanoscale ... Inc., a developer,of breakthrough nanoscale whole genome imaging platforms ... appointment of noted biophysicist Paul R. Selvin, Ph.D., to ...
... and Storage Systems Fuel Faster Time to Discovery for ... Researchers Seeking Causes and Cures of Disease, BOSTON, April ... As scientists seek to accelerate sequencing,genomes of varied arrays of ... determine causes and cures of diseases that plague mankind,breakthrough technology ...
Cached Biology Technology:ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform 2BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board 2BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board 3SGI Breakthrough Technology Empowers Genome Center Research Around the World 2SGI Breakthrough Technology Empowers Genome Center Research Around the World 3SGI Breakthrough Technology Empowers Genome Center Research Around the World 4SGI Breakthrough Technology Empowers Genome Center Research Around the World 5
(Date:5/22/2013)... CITY, May 22, 2013 U.S. Forest Service scientists ... that, with funding from the TKF Foundation, will examine ... communities and individuals recover from tragedy. , The TKF ... of six projects selected for grant funding. In addition ... sacred spaces in recovery and resiliency, the 3-year, $585,000 ...
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Tests lead to doubling of fuel cell life 2
... MD, received the 2010 Recognition Award for Scientific Accomplishments ... Monday, May 17. , Dr. Downey, Executive Vice President ... Immunology at National Jewish Health, has over 190 publications ... authors more than 5,000 times, putting him in the ...
... - (May 17, 2010) In the Opening Session ... National Biotechnology Conference, AAPS President Danny D. Shen, Ph.D., ... contributions to the pharmaceutical sciences: Excellence in ... , From ANP Technologies, Inc.: Ray Yin; Yli ...
... Ind. - Using NASA satellite data and Google Earth, ... North Korea has been logging in what is designated ... Shao, professor of geo-eco-informatics, studies the Mount Paekdu Biosphere ... many researchers are unable to visit North Korea, Shao ...
Cached Biology News:Gregory Downey, M.D., of National Jewish Health, honored for scientific accomplishments 2AAPS announces 2010 NBC award winners 2NASA, Google data show North Korea logging in protected area 2
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Biology Products: